<?xml version="1.0" encoding="UTF-8"?><akomaNtoso xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0" xmlns:fmx="http://formex.publications.europa.eu/schema/formex-05.21-20110601.xd" xmlns:leos="urn:eu:europa:ec:leos" xmlns:xs="http://www.w3.org/2001/XMLSchema"><bill name=""><meta xmlns:fn="http://www.w3.org/2005/xpath-functions"><identification source="~COM"><FRBRWork><FRBRthis value=""/><FRBRuri value=""/><FRBRdate date="2999-01-01" name=""/><FRBRauthor href=""/><FRBRcountry value=""/></FRBRWork><FRBRExpression><FRBRthis value=""/><FRBRuri value=""/><FRBRdate date="2999-01-01" name=""/><FRBRauthor href=""/><FRBRlanguage language="eng"/></FRBRExpression><FRBRManifestation><FRBRthis value=""/><FRBRuri value=""/><FRBRdate date="2999-01-01" name=""/><FRBRauthor href=""/></FRBRManifestation></identification></meta><preface><longTitle><p><docStage/><docType>COMMISSION IMPLEMENTING DECISION (EU) 2020/350</docType>of 28 February 2020<docPurpose>amending Decision 2002/364/EC as regards definitions of first&#45;line assays and confirmatory assays, requirements for devices for self-testing and requirements for HIV and HCV rapid tests, confirmatory and supplementary assays</docPurpose></p></longTitle><container name="EEArelevance"><p>(notified under document C(2020) 1086)</p></container></preface><preamble><formula name="actingEntity"><p>THE EUROPEAN COMMISSION,</p></formula><citations><citation><p>Having regard to the Treaty on the Functioning of the European Union,</p></citation><citation><p>Having regard to Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on <i>in vitro</i> diagnostic medical devices<authorialNote placement="bottom" marker="1"><p>OJ L 331, 7.12.1998, p. 1.</p></authorialNote>, and in particular the second subparagraph of Article 5(3) thereof,</p></citation></citations><recitals xml:id="recs_d243e78"><intro><p>Whereas:</p></intro><recital xml:id="rec_d243e81"><num>(1)</num><p>Pursuant to the first subparagraph of Article 5(3) of Directive 98/79/EC, Member States are to presume compliance with the essential requirements referred to in Article 3 of that Directive in respect of devices designed and manufactured in conformity with common technical specifications. The common technical specifications for in vitro diagnostic medical devices are laid down in Commission Decision 2002/364/EC<authorialNote placement="bottom" marker="2"><p>Commission Decision 2002/364/EC of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (OJ L 131, 16.5.2002, p. 17).</p></authorialNote>.</p></recital><recital xml:id="rec_d243e97"><num>(2)</num><p>In the interest of public health and patient safety and in order to reflect scientific and technological progress, including the evolution in the intended use, performance, and analytical sensitivity of certain devices, it is appropriate to update the common technical specifications laid down in Decision 2002/364/EC.</p></recital><recital xml:id="rec_d243e103"><num>(3)</num><p>The definitions of first-line assays and confirmatory assays, requirements for devices for self-testing and requirements for HIV and HCV rapid tests, confirmatory and supplementary assays should be amended in order to take into account the evolved state of the art, the changes in clinical needs, new scientific knowledge available and the new types of devices present on the market.</p></recital><recital xml:id="rec_d243e109"><num>(4)</num><p>The manufacturers should be allowed time to adapt to the changes in common technical specifications. The date of application of this Decision should therefore be deferred. However, in the interest of public health and patient safety, manufacturers should be allowed to comply with the common technical specifications as amended by this Decision before its date of application on a voluntary basis.</p></recital><recital xml:id="rec_d243e115"><num>(5)</num><p>The measures provided for in this Decision are in accordance with the opinion of the Committee established by Article 6(2) of Council Directive 90/385/EEC<authorialNote placement="bottom" marker="3"><p>Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices (OJ L 189, 20.7.1990, p. 17).</p></authorialNote>,</p></recital></recitals><formula name="enactingFormula"><p>HAS ADOPTED THIS DECISION:</p></formula></preamble><body><article xml:id="art_d243e135"><num>Article 1</num><heading/><paragraph><content><p>The Annex to Decision 2002/364/EC is amended in accordance with the Annex to this Decision.</p></content></paragraph></article><article xml:id="art_d243e140"><num>Article 2</num><heading/><paragraph><num>1.</num><content><p>This Decision shall apply from 2 March 2021.</p></content></paragraph><paragraph><num>2.</num><subparagraph><content><p>Notwithstanding paragraph 1, from 2 March 2020 until 1 July 2020 Member States shall apply the presumption of compliance laid down in Article 5(3) of Directive 98/79/EC for all in vitro diagnostic medical devices that comply with any of the following:</p></content></subparagraph><list><point><num>(a)</num><content><p>the common technical specifications laid down in Decision 2002/364/EC as amended by Commission Decision 2011/869/EU<authorialNote placement="bottom" marker="4"><p>Commission Decision 2011/869/EU of 20 December 2011 amending Decision 2002/364/EC on common technical specifications for in vitro diagnostic medical devices (OJ L 341, 22.12.2011, p. 63).</p></authorialNote>;</p></content></point><point><num>(b)</num><content><p>the common technical specifications laid down in Decision 2002/364/EC as amended by Commission Implementing Decision (EU) 2019/1244<authorialNote placement="bottom" marker="5"><p>Commission Implementing Decision (EU) 2019/1244 of 1 July 2019 amending Decision 2002/364/EC as regards requirements for HIV and HCV antigen and antibody combined tests and as regards requirements for nucleic acid amplification techniques with respect to reference materials and qualitative HIV assays (OJ L 193, 19.07.2019, p.1).</p></authorialNote>;</p></content></point><point><num>(c)</num><content><p>the common technical specifications laid down in Decision 2002/364/EC as amended by this Decision.</p></content></point></list></paragraph><paragraph><num>3.</num><subparagraph><content><p>Notwithstanding paragraph 1, from 2 July 2020 until 1 March 2021 Member States shall apply the presumption of compliance laid down in Article 5(3) of Directive 98/79/EC for all in vitro diagnostic medical devices that comply with either of the following:</p></content></subparagraph><list><point><num>(a)</num><content><p>the common technical specifications laid down in Decision 2002/364/EC as amended by Implementing Decision (EU) 2019/1244;</p></content></point><point><num>(b)</num><content><p>the common technical specifications laid down in Decision 2002/364/EC as amended by this Decision.</p></content></point></list></paragraph></article><article xml:id="art_d243e227"><num>Article 3</num><heading/><paragraph><content><p>This Decision is addressed to the Member States.</p></content></paragraph></article></body><conclusions><p>Done at Brussels, 28 February 2020.</p><block name="signatory"><signature><organization refersTo="">For the Commission</organization><role refersTo="">Stella KYRIAKIDES</role><person refersTo="">Member of the Commission</person></signature></block></conclusions></bill></akomaNtoso>